Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow HARVARD BIOSCIENCE INC

Get SEC filing alerts via email and in your feed for HARVARD BIOSCIENCE INC

HBIO

HARVARD BIOSCIENCE INC

About HARVARD BIOSCIENCE INC

Harvard Bioscience, Inc. develops and sells life science research tools, including cellular, molecular, and preclinical testing products. Its offerings support drug discovery, bioproduction, and organoid research for academic, government, and pharmaceutical customers worldwide. The company emphasizes innovation, product portfolio expansion, and operational efficiency to maintain competitive advantage in a highly dynamic industry. It operates globally, serving diverse research and biotech markets with proprietary and distributed products.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from HARVARD BIOSCIENCE INC

1
1
HARVARD BIOSCIENCE INC Harvard Bioscience Reports $20.8M Revenue in Q1 2026, Net Loss Improves to $3.4M

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
HARVARD BIOSCIENCE INC Harvard Bioscience Reports 8.1% Revenue Decline and Implements Strategic Consolidation Plan

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
HARVARD BIOSCIENCE INC Harvard Bioscience Reports 6.3% Revenue Decline in Q3 2025 Amid Financial Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
HARVARD BIOSCIENCE INC Harvard Bioscience Reports 11.5% Revenue Decline and $52.6 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
HARVARD BIOSCIENCE INC Harvard Bioscience Reports 11.2% Revenue Decline and $50.3 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
HARVARD BIOSCIENCE INC Harvard Bioscience Reports 16.1% Revenue Decline and $12.4 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
HARVARD BIOSCIENCE INC Harvard Bioscience Reports Significant Financial Challenges, Decline in Revenues and Net Losses

Via official filing (AI summary) | over 1 year ago | 0 comments